THELIN TABLET
Land: Canada
Språk: engelsk
Kilde: Health Canada
Preparatomtale
(SPC)
13-05-2010
Noen dokumenter for dette produktet er ikke tilgjengelig for øyeblikket, du kan sende en forespørsel til kundeservicen vår, og vi vil varsle deg så snart vi kan få dem.
Send forespørsel.
Send forespørsel.
Aktiv ingrediens:
SITAXSENTAN SODIUM
Tilgjengelig fra:
PFIZER CANADA ULC
ATC-kode:
C02KX03
INN (International Name):
SITAXENTAN
Dosering :
100MG
Legemiddelform:
TABLET
Sammensetning:
SITAXSENTAN SODIUM 100MG
Administreringsrute:
ORAL
Enheter i pakken:
28
Resept typen:
Prescription
Terapeutisk område:
MISCELLANEOUS VASODILATATING AGENTS
Produkt oppsummering:
Active ingredient group (AIG) number: 0152215001; AHFS:
Autorisasjon status:
CANCELLED POST MARKET
Autorisasjon dato:
2011-04-30
Preparatomtale
_ _
_ _
_PR_
_THELIN_
_® _
_(sitaxsentan sodium tablets) Product Monograph _
_Page 1 of 28_
PRODUCT MONOGRAPH
PR
THELIN
®
(sitaxsentan sodium tablets)
100 mg
Endothelin receptor antagonist
® Registered trademark of Encysive Pharmaceuticals Inc.
Pfizer Canada Inc.
17 300 Trans-Canada Highway
Kirkland, Quebec H9J 2M5
Date of preparation:
April 26, 2010
Submission Control Number: 134705
_ _
_ _
_PR_
_THELIN_
_® _
_(sitaxsentan sodium tablets) Product Monograph _
_Page 2 of 28_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION................................................... 3
SUMMARY OF PRODUCT INFORMATION
............................................................. 3
INDICATIONS AND CLINICAL
USE.........................................................................
3
CONTRAINDICATIONS
..............................................................................................
3
DOSAGE AND
ADMINISTRATION.........................................................................
13
OVERDOSAGE:
..........................................................................................................
14
ACTION AND CLINICAL PHARMACOLOGY
....................................................... 15
STORAGE AND
STABILITY.....................................................................................
16
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................ 16
PART II: SCIENTIFIC
INFORMATION........................................................................
18
PHARMACEUTICAL
INFORMATION.....................................................................
18
CLINICAL
TRIALS.....................................................................................................
19
DETAILED
PHARMACOLOGY................................................................................
21
TOXICOLOGY
............................................................................................................
24
REFERENCES
.................................................................
Les hele dokumentet
